Suzanne Trudel
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Suzanne Trudel.
Journal of Clinical Oncology | 2008
D. Reece; Giovanni Piza Rodriguez; Christine Chen; Suzanne Trudel; Vishal Kukreti; Joseph R. Mikhael; Mariela Pantoja; Wei Xu; A. Keith Stewart
PURPOSE The combination of oral weekly cyclophosphamide and alternate day prednisone is a convenient regimen for relapsed/refractory multiple myeloma (MM), and we sought to improve its efficacy by adding bortezomib, a proteasome inhibitor with proven antimyeloma activity. PATIENTS AND METHODS We conducted a phase I-II trial evaluating six dose levels to define the maximum tolerated dose (MTD) of this combination in relapsed/refractory MM. An additional 10 patients were evaluated at the highest dose level reached. RESULTS Thirty-seven patients were treated on this study. The MTD was not defined. Both of the highest dose levels of bortezomib tested (1.3 mg/m(2) on days 1, 4, 8, and 11 and 1.5 mg/m(2) on days 1, 8, and 15, each on a 28-day cycle) could be safely given with cyclophosphamide 300 mg/m(2) per week and prednisone. At these dose levels, the overall response rate was 95% (complete responses [CR] plus partial response plus minimal response), with CR observed in more than 50% of patients. The weekly bortezomib regimen resulted in fewer instances of grade 3 thrombocytopenia and grade 1 to 2 peripheral neuropathy; the 1-year progression-free and overall survival probabilities with this dose level were 83% (95% CI, 73% to 96%) and 100%, respectively. CONCLUSION Weekly bortezomib 1.5 mg/m(2) plus oral cyclophosphamide and prednisone produces an unprecedented response rate and encouraging 1-year survival in relapsed/refractory patients with MM. Further evaluation of this promising regimen is warranted both in relapsed and newly diagnosed disease.
Leukemia | 2007
Ak K. Stewart; Hong Chang; Suzanne Trudel; Kc C. Anderson; Paul G. Richardson; Melissa Alsina; D. Reece; Scott W. Young; Alicia Sable-Hunt; Zhuo Li; Jonathan J. Keats; S. Van Wier; Gregory J. Ahmann; Tammy Price-Troska; Kathy Giusti; P L Bergsagel; Martha Chesi; Rafael Fonseca
The presence of a t(4;14) in multiple myeloma (MM) is associated with significantly inferior outcomes following both conventional chemotherapy and high-dose melphalan-based treatment regimens.1, 2 Detection of patients bearing the t(4;14) is therefore important in an MM molecular workup. Furthermore, since targeted inhibitors of the associated fibroblast growth factor receptor 3 (FGFR3) tyrosine kinase are now in clinical trials,3 detection of MM patients who express the FGFR3 protein is also of potential therapeutic relevance. With this in mind, we have employed the infrastructure of the Multiple Myeloma Research Consortium (MMRC) tissue bank to evaluate four different methodologies for the molecular diagnostic detection of this translocation. The methods employed are published previously4, 5, 6 or are provided as Supplementary Information.
Biology of Blood and Marrow Transplantation | 2009
Parneet K. Cheema; Sahar Zadeh; Vishal Kukreti; D. Reece; Christine Chen; Suzanne Trudel; Joseph R. Mikhael
Multiple myeloma (MM) rarely occurs in patients 40 years of age and younger. This young age has been reported to correlate with improved survival in patients with MM. The objective of this study is to describe presenting features and outcomes of patients < or =40 years of age with MM who undergo autologous stem cell transplantation (ASCT) as first-line treatment, and compare overall survival (OS) and progression free survival (PFS) to patients aged 41-65 years. We performed a retrospective institutional review of all patients < or =40 years of age and 41-65 years of age at the time of diagnosis of MM who had undergone upfront ASCT from January 1, 1990, to July 31, 2007. Thirty-eight patients < or =40 years of age and 608 patients aged 41-65 were identified. There was a high rate of plasma cell leukemia (PCL) in young patients at 11% compared to the reported rate of 2%-4%. At diagnosis, there was an increased rate of renal failure in the young cohort compared to patients aged 41-65 years at 25% versus 16% and Bence Jones proteinuria at 81% versus 51%. The rate of complete or partial response was similar between the groups at 79% and 83% in the young and older cohorts, respectively. Median PFS post-ASCT was 22.0 months (95% confidence interval [CI]: 16.1, 28.0), versus 26.9 months (95% CI: 24.0, 29.8) for patients aged 41-65 years (P = .66). Median OS from date of ASCT was also similar to those over 40 years: 68.1 months (95% CI: 39.0, 97.2) versus 80.7 months (95% CI: 68.1, 93.4); P = .90. Treatment-related mortality (TRM) was low at 2.6% and 2.3% in the young and older cohorts, respectively. Despite previous reports that young age is a positive prognostic marker, our study found OS post-ASCT is equivalent to those aged 41-65 years. This study emphasizes the importance of developing strategies to better the outcomes of young patients with MM.
Blood | 2006
Esther Masih-Khan; Suzanne Trudel; Carla Heise; Zhihua Li; Joshua Paterson; Vincent Nadeem; Ellen Wei; David Roodman; Jaime O. Claudio; P. Leif Bergsagel; A. Keith Stewart
Archive | 2006
Carla Heise; Esther Masih-Khan; Edward Moler; Michael Rowe; Keith Stewart; Suzanne Trudel
Journal of Clinical Oncology | 2008
Craig B. Reeder; A. K. Stewart; J. G. Hentz; P. L. Bergsagel; Nicholas Pirooz; Rafael Fonseca; Christine Chen; Suzanne Trudel; D. Reece; Vishal Kukreti
Blood | 2008
Seda Zeng; Zhihua Li; Marta Chesi; Chungyee Leung-Hagesteijn; Shengben Liang; P. Leif Bergsagel; Suzanne Trudel
Biology of Blood and Marrow Transplantation | 2006
Joseph R. Mikhael; S. Samiee; A. K. Stewart; Christine Chen; Suzanne Trudel; Norman Franke; Andrew Winter; D. Phillips; D. Reece
Blood | 2005
Esther Masih-Khan; Suzanne Trudel; Zhihua Li; Vincent Nadeem; Ellen Wei; Joshua Paterson; Jaime O. Claudio; A. Keith Stewart
Blood | 2007
Xinliang Mao; A. Keith Stewart; Rose Hurren; Marcela Gronda; Kyle Lee; Sue Chow; Shengben Liang; Suzanne Trudel; David W. Hedley; Aaron D. Schimmer